Vistagen Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Vistagen Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Mar 31, 2023 | $176.0K | Jun 28, 2023 |
| FY2023 | Dec 31, 2022 | $180.0K | Jun 28, 2023 |
| FY2023 | Sep 30, 2022 | ($893.0K) | Jun 28, 2023 |
| FY2023 | Jun 30, 2022 | $310.0K | Jun 28, 2023 |
| FY2023 | Mar 31, 2022 | $39.0K | Jun 28, 2023 |
| FY2023 | Dec 31, 2021 | $358.0K | Jun 28, 2023 |
| FY2023 | Sep 30, 2021 | $358.0K | Jun 28, 2023 |
| FY2023 | Jun 30, 2021 | $354.0K | Jun 28, 2023 |
| FY2021 | Mar 31, 2021 | $442.0K | Jun 29, 2021 |
| FY2021 | Dec 31, 2020 | $314.0K | Jun 29, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($51.42M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($29.36M) | Jun 17, 2025 |
| FY2023 | Mar 31, 2023 | ($12.23M) | Jun 28, 2023 |
| FY2023 | Dec 31, 2022 | ($9.76M) | Jun 28, 2023 |
| FY2023 | Sep 30, 2022 | ($17.48M) | Jun 28, 2023 |
| FY2023 | Jun 30, 2022 | ($19.78M) | Jun 28, 2023 |
| FY2023 | Mar 31, 2022 | ($16.69M) | Jun 28, 2023 |
| FY2023 | Dec 31, 2021 | ($10.53M) | Jun 28, 2023 |
| FY2023 | Sep 30, 2021 | ($12.80M) | Jun 28, 2023 |
| FY2023 | Jun 30, 2021 | ($7.75M) | Jun 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($55.97M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($33.02M) | Jun 17, 2025 |
| FY2023 | Mar 31, 2023 | ($12.24M) | Jun 28, 2023 |
| FY2023 | Dec 31, 2022 | ($9.77M) | Jun 28, 2023 |
| FY2023 | Sep 30, 2022 | ($17.49M) | Jun 28, 2023 |
| FY2023 | Jun 30, 2022 | ($19.77M) | Jun 28, 2023 |
| FY2023 | Mar 31, 2022 | ($16.69M) | Jun 28, 2023 |
| FY2023 | Dec 31, 2021 | ($10.54M) | Jun 28, 2023 |
| FY2023 | Sep 30, 2021 | ($12.80M) | Jun 28, 2023 |
| FY2023 | Jun 30, 2021 | ($7.75M) | Jun 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $39.38M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $20.02M | Jun 17, 2025 |
| FY2023 | Mar 31, 2023 | $9.34M | Jun 28, 2023 |
| FY2023 | Dec 31, 2022 | $6.85M | Jun 28, 2023 |
| FY2023 | Sep 30, 2022 | $12.90M | Jun 28, 2023 |
| FY2023 | Jun 30, 2022 | $15.29M | Jun 28, 2023 |
| FY2023 | Mar 31, 2022 | $12.23M | Jun 28, 2023 |
| FY2023 | Dec 31, 2021 | $7.78M | Jun 28, 2023 |
| FY2023 | Sep 30, 2021 | $9.94M | Jun 28, 2023 |
| FY2023 | Jun 30, 2021 | $5.46M | Jun 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($42.10M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($25.81M) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | ($49.72M) | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | ($45.26M) | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | ($12.07M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | ($15.76M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($14.53M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($9.06M) | Jun 25, 2019 |
| FY2015 | Mar 31, 2015 | ($2.77M) | Jun 29, 2015 |
| FY2015 | Mar 31, 2014 | ($2.13M) | Jun 29, 2015 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Mar 31, 2022 | $200.4K | Jun 23, 2022 |
| FY2022 | Mar 31, 2021 | $275.4K | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $0 | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $174.0K | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $1.6K | Jun 25, 2019 |
| FY2018 | Mar 31, 2017 | $239.1K | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $26.3K | Jun 29, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $84.34M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $123.65M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $21.09M | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | $74.64M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $108.28M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $5.77M | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $14.01M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $11.28M | Jun 25, 2019 |
| FY2018 | Mar 31, 2017 | $3.71M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $989.8K | Jun 29, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $13.95M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $9.37M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $9.01M | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | $9.93M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $16.30M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $11.50M | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | $6.94M | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | $4.36M | Jun 25, 2019 |
| FY2018 | Mar 31, 2017 | $3.10M | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | $3.97M | Jun 29, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $70.39M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $114.29M | Jun 17, 2025 |
| FY2025 | Mar 31, 2023 | $12.08M | Jun 17, 2025 |
| FY2024 | Mar 31, 2022 | $64.72M | Jun 11, 2024 |
| FY2023 | Mar 31, 2021 | $91.98M | Jun 28, 2023 |
| FY2022 | Mar 31, 2020 | ($5.73M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2019 | $7.08M | Jun 29, 2021 |
| FY2020 | Mar 31, 2018 | $6.92M | Jun 29, 2020 |
| FY2019 | Mar 31, 2017 | $615.8K | Jun 25, 2019 |
| FY2018 | Mar 31, 2016 | ($2.98M) | Jun 26, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($407.63M) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | ($356.21M) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | ($326.85M) | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | ($267.60M) | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | ($219.84M) | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | ($201.91M) | Jun 29, 2021 |
| FY2020 | Mar 31, 2019 | ($181.13M) | Jun 29, 2020 |
| FY2019 | Mar 31, 2018 | ($156.54M) | Jun 25, 2019 |
| FY2018 | Mar 31, 2017 | ($142.00M) | Jun 26, 2018 |
| FY2017 | Mar 31, 2016 | ($131.74M) | Jun 29, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $67.13M | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | $119.17M | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | $16.64M | Jun 11, 2024 |
| FY2023 | Mar 31, 2022 | $68.14M | Jun 28, 2023 |
| FY2022 | Mar 31, 2021 | $103.11M | Jun 23, 2022 |
| FY2021 | Mar 31, 2020 | $1.36M | Jun 29, 2021 |
| FY2021 | Mar 31, 2019 | $13.10M | Jun 29, 2021 |
| FY2020 | Mar 31, 2018 | $10.38M | Jun 29, 2020 |
| FY2019 | Mar 31, 2017 | $2.92M | Jun 25, 2019 |
| FY2018 | Mar 31, 2016 | $428.5K | Jun 26, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2016 | Mar 31, 2016 | $58.8K | Jun 24, 2016 |
| FY2016 | Mar 31, 2015 | $1.51M | Jun 24, 2016 |
| FY2014 | Mar 31, 2014 | $2.06M | Jun 25, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (1) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | (1) | Jun 17, 2025 |
| FY2023 | Mar 31, 2023 | (1) | Jun 28, 2023 |
| FY2023 | Dec 31, 2022 | (1) | Jun 28, 2023 |
| FY2023 | Sep 30, 2022 | (2) | Jun 28, 2023 |
| FY2023 | Jun 30, 2022 | (2) | Jun 28, 2023 |
| FY2023 | Mar 31, 2022 | (2) | Jun 28, 2023 |
| FY2023 | Dec 31, 2021 | (1) | Jun 28, 2023 |
| FY2023 | Sep 30, 2021 | (2) | Jun 28, 2023 |
| FY2023 | Jun 30, 2021 | (1) | Jun 28, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | (1) | Jun 17, 2025 |
| FY2025 | Mar 31, 2024 | (1) | Jun 17, 2025 |
| FY2024 | Mar 31, 2023 | (8) | Jun 11, 2024 |
| FY2016 | Mar 31, 2016 | (29) | Jun 24, 2016 |
| FY2016 | Mar 31, 2015 | (4) | Jun 24, 2016 |
| FY2016 | Dec 31, 2014 | (1) | Jun 24, 2016 |
| FY2016 | Sep 30, 2014 | (1) | Jun 24, 2016 |
| FY2016 | Jun 30, 2014 | (3) | Jun 24, 2016 |
| FY2015 | Mar 31, 2014 | (1) | Jun 29, 2015 |
| FY2015 | Dec 31, 2013 | 0 | Jun 29, 2015 |